The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit? 

Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast. 

Take our post-test to claim CME credits.

Read this podcast's companion newsletter here.

Hosted on Acast. See acast.com/privacy for more information.